头孢克洛治疗慢性阻塞性肺疾病继发下呼吸道感染(英文)

Cefaclor in treatment of secondary lower respiratory tract infections in chronic obstructive pulmonary diseases

目的 :评估头孢克洛治疗轻、中度慢性阻塞性肺疾病 (COPD)继发下呼吸道感染的临床疗效和安全性。方法 :对 180例COPD病人 (男性 118例 ,女性 6 2例 ,年龄 6 4a±s 15a)并发下呼吸道感染进行多中心开放试验。口服头孢克洛 2 5 0mg ,tid ,以7～ 14d为一个疗程。结果 :临床总有效率 91.1%(16 4 /180 )。 180例咳痰培养分离到 92株病原菌。头孢克洛对全部分离的细菌的敏感性和清除率分别为 70 %和 6 8% ,头孢克洛对其抗菌谱覆盖细菌的敏感性和清除率分别为 97%和 94 %。不良反应发生率为 3.9% (7/180 )。结论 :头孢克洛仍是十分有效、安全的治疗COPD继发轻。

AIM: To evaluate the clinical efficacy and safety of cefaclor in treatment of secondary lower respiratory tract infections in chronic obstructive pulmonary diseases(COPD). METHODS: Multicenter open clinical trial was conducted. One hundred and eighty patients (M 118,F 62; 64 a± s 15 a) with secondary lower respiratory tract infections in COPD were enrolled into this study. Cefaclor,250 mg, po , tid, was administered orally for 7 14 d. The clinical efficacy, bacteriological response and adverse reactions were observed. RESULTS: Total effective rate was 91.1 % (164/180 including cured 86,significant improvement 78, improvement 13, failure 3). Ninety two strains of bacteria were isolated from expectorated sputum culture in 180 patients, including 29 strains of gram positive cocci and 63 trains of gram negative bacilli. The sensitive rate and eradication rate of cefaclor to the whole isolated organisms were 70 % ( 64/ 92) and 68 % (63/92)respectively, however, the sensitive rate and eradication rate of cefaclor to the organisms within cefaclor's antibacterial spectrum were 97 % and 94 % respectively. The total adverse reaction rate was 3.9 % (7/180). There was no abnormal change in renal and hepatic function induced by cefaclor through laboratory test comparison before and after cefaclor therapy in 53 patients. CONCLUSION: Cefaclor is still a very effective and safe antibiotic for secondary mild and moderate lower respiratory tract infections of COPD.